Trial Profile
A phase IIa trial of OPT-302 in previously treated patients with wet age-related macular degeneration
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 03 May 2017
Price :
$35
*
At a glance
- Drugs Sozinibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Opthea
- 03 May 2017 New trial record
- 28 Apr 2017 According to an Opthea media release, the company plans to initiate this trial in the second half of 2017.